ConductScience.org, home

Paper41345397

Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion.

Iyengar NM and 9 others. NPJ Breast Cancer, 2025. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion. Papers, record 41345397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41345397

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion.
PubMed
Journal
NPJ Breast Cancer
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
1.11, provisional
iCite
Revised in PubMed
2026-03-10
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Iyengar NMNeil M
2O'Shaughnessy JAJoyce A
3Moore HNHeather N
4Hamilton EErika
5Jhaveri KLKomal L
6Ma CXCynthia X
7Tedesco KKaren
8Vasekar MMonali
9Donahue SSarah
10Rugo HSHope S

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed

Source NIH RePORTER

Download CSV of grants

References56

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136187122Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials.Front Endocrinol (Lausanne)2022https://conductscience.org/library/papers/36187122PubMed
226240704Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review.World J Diabetes2015https://conductscience.org/library/papers/26240704PubMed
3349648752. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022.Diabetes Care2022https://conductscience.org/library/papers/34964875PubMed
438478799Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.J Clin Oncol2024https://conductscience.org/library/papers/38478799PubMed
525057302The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.Ther Adv Med Oncol2014https://conductscience.org/library/papers/25057302PubMed
634916492Targeting PI3K/Akt signal transduction for cancer therapy.Signal Transduct Target Ther2021https://conductscience.org/library/papers/34916492PubMed
731629292Gastrointestinal tract metastasis presenting as intussusception in invasive lobular carcinoma of the breast: A case report.Int J Surg Case Rep2019https://conductscience.org/library/papers/31629292PubMed
838297009Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.NPJ Breast Cancer2024https://conductscience.org/library/papers/38297009PubMed
924197877Detection of intestinal protozoa in the clinical laboratory.J Clin Microbiol2014https://conductscience.org/library/papers/24197877PubMed
1033719380Topical Corticosteroids: Choice and Application.Am Fam Physician2021https://conductscience.org/library/papers/33719380PubMed
1131091374Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med2019https://conductscience.org/library/papers/31091374PubMed
1234067630The PI3K/Akt Pathway: Emerging Roles in Skin Homeostasis and a Group of Non-Malignant Skin Disorders.Cells2021https://conductscience.org/library/papers/34067630PubMed
1324611020Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes.Diabetes Metab Syndr Obes2014https://conductscience.org/library/papers/24611020PubMed
1431626273Management of toxicity to isoform α-specific PI3K inhibitors.Ann Oncol2019https://conductscience.org/library/papers/31626273PubMed
1530649751Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.Drug Saf2019https://conductscience.org/library/papers/30649751PubMed
1632613539Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.Breast Cancer Res Treat2020https://conductscience.org/library/papers/32613539PubMed
1738812089The PI3K/Akt signaling axis and type 2 diabetes mellitus (T2DM): From mechanistic insights into possible therapeutic targets.Cell Biol Int2024https://conductscience.org/library/papers/38812089PubMed
1835372075Systemic Deficiency of PTEN Accelerates Breast Cancer Growth and Metastasis.Front Oncol2022https://conductscience.org/library/papers/35372075PubMed
1939241495
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.
ESMO Open2024https://conductscience.org/library/papers/39241495PubMed
2039690017Acute hyperglycemic hyperosmolar syndrome associated with capivasertib, a new, oral targeted therapy for advanced breast cancer.Am J Emerg Med2025https://conductscience.org/library/papers/39690017PubMed

See all 56 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42865609Capivasertib-Associated Diabetic Ketoacidosis With Concurrent Myocardial Injury in a Patient With Pre-Existing Coronary Artery Disease.Case Rep Endocrinol2026https://conductscience.org/library/papers/42865609PubMed
42792909AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with EGFR Mutation.Genes (Basel)2026https://conductscience.org/library/papers/42792909PubMed
42443498Transcription factor targeting strategies in cancer: mechanisms, challenges and cutting-edge progress.Acta Pharmacol Sin2026https://conductscience.org/library/papers/42443498PubMed
42266036Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer.Oncologist2026https://conductscience.org/library/papers/42266036PubMed
42194764Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance.J Clin Med2026https://conductscience.org/library/papers/42194764PubMed
42041716
Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.
Curr Oncol2026https://conductscience.org/library/papers/42041716PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164NCBI Gene
PIK3CA5290PubTator's text mininghttps://conductscience.org/library/genes/5290NCBI Gene
PTEN5728PubTator's text mininghttps://conductscience.org/library/genes/5728NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41345397

GET https://conductscience.org/api/papers/v1/41345397/references?page=2